-48%

est. 2Y upside i

HealthcareAI & MLSeries A

Generative AI for Oncology EHRs

Rank

#434

Sector

Healthtech, AI

Est. Liquidity

~4Y

Data Quality

Data: Medium

Triomics presents a strong upside opportunity for a job seeker, driven by its specialized AI in oncology and significant market potential.

Last updated: March 10, 2026

Bull (30%)+350%

Triomics' proprietary OncoLLM and deep EHR integrations become the industry standard for oncology workflow automation, expanding beyond clinical trials into broader cancer care management. Strategic partnerships with major pharmaceutical companies and additional cancer centers drive revenue to $100M+ by 2028, justifying an acquisition or IPO at a $810M+ valuation (4.5x current estimated valuation) due to its specialized AI advantage and significant market penetration.

Base (40%)+100%

Triomics successfully expands its customer base within oncology, maintaining strong growth in clinical trial matching and data curation. It carves out a solid niche against general AI and broader healthtech platforms, reaching approximately $40M in annual recurring revenue by 2028. This growth supports an exit at a $360M valuation (2x current estimated valuation), reflecting continued market traction and product maturity.

Bear (30%)-80%

Dominant healthcare incumbents (e.g., Epic, Oracle Health) or well-funded AI competitors develop or acquire similar specialized oncology AI solutions, commoditizing Triomics' core offerings. This leads to slower-than-expected customer acquisition and pricing pressure, with revenue growth stalling. A down round or acquisition at a significantly reduced valuation of $36M (0.2x current estimated valuation) wipes out most common stock value due to liquidation preferences.

Est. time to liquidity~3.5 years

Preference Stack Risk

high

Investors hold $29M in liquidation preferences ahead of common stock, representing 16.11% of the estimated current $180M valuation.

Dilution Risk

moderate

As a Series A company, Triomics will likely require 1-2 additional funding rounds (Series B, C) before a liquidity event, leading to further dilution for early equity holders.

Secondary Liquidity

none

Given its early stage (Series A), there is currently no active secondary market or tender offers for Triomics' equity.

Questions to Ask at the Interview

Strategic questions based on Triomics's data — designed to show you've done your homework.

  • 1

    “Given the success of OncoLLM in clinical trial matching, how is Triomics planning to expand its application to other critical oncology workflows, and what are the biggest technical or adoption challenges anticipated?”

  • 2

    “With a TAM of $33.7B and current market penetration at only ~5%, what is Triomics' strategy to accelerate market penetration and scale its ~$8M revenue significantly over the next 2-3 years?”

  • 3

    “Considering the Series A funding and the high preference stack, what is the company's long-term vision for liquidity for employees, and what milestones are critical to achieving that?”

Community

Valuation Sentiment

Our model estimates -48% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.